ArticleToxicology research2025
Structural insights and predictive modelling of a novel anti-HER2 scFv and Leptulipin: a newly designed immunotoxin protein for HER2 positive cancers.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted therapy is one crucial therapeutic approach frequently employed in cancer treatment. In almost 30% of human breast cancers, a transmembrane tyrosine kinase receptor named the HER2 (human epidermal growth factor receptor 2) is overexpressed, establishing HER-2 as a promising target for cancer treatment. The goal of the current work is to computationally design and analyze a new chimeric protein that could selectively target HER2-positive breast cancer cells based on a single polypeptide chain variable fragment and leptulipin (an anticancer peptide) fusion. After the computational joining of the secondary structure, 3D modeling, quality validation, physicochemical properties, docking, interaction analysis, MD simulation, and energy calculations were performed using various computational tools and online servers. The most precise predicted chimeric protein model was docked to the HER-2 receptor using ClusPro 2.0, which revealed a significant number of hydrogen bonds and salt bridges reflecting the fusion protein's quality, validity, interaction, and stability. These results were further supported by MD simulation on the Desmond Schrodinger module, which predicted a stable docked complex. This was also evident by principal component analysis and the negative energy value of MM/PBSA. These comprehensive in silico analyses, coupled with a high predicted expression value of 0.94 in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.